Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer | Zendy

Wiggans R. Glen | Zendy; Woolley Paul V. | Zendy; Macdonald John S. | Zendy; Smythe Tarilyn | Zendy; Ueno Winston | Zendy; Schein Philip S. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer

Author(s) -

Wiggans R. Glen,

Woolley Paul V.,

Macdonald John S.,

Smythe Tarilyn,

Ueno Winston,

Schein Philip S.

Publication year - 1978

Publication title -

cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.052

H-Index - 304

eISSN - 1097-0142

pISSN - 0008-543X

DOI - 10.1002/1097-0142(197802)41:2<387::aid-cncr2820410201>3.0.co;2-x

Subject(s) - medicine , nausea , mitomycin c , gastroenterology , regimen , azotemia , vomiting , fluorouracil , streptozotocin , progressive disease , surgery , chemotherapy , diabetes mellitus , endocrinology , renal function

Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent azotemia in 9% of patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research